EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial

Xiaobo Yang, Jingye Pan, Xun Gong, Ailian Lv, Fengming Liang, Jing Liu, Dezhong Li, Shouzhi Fu, Aijun Pan, Li Yu, Lina Zhang, Tao Chen und 16 weitere

Intensive Care Medicine · 2026-05 · 52 (5) · 1001-1011

DOI: 10.1007/s00134-026-08381-x ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Intensive Care Medicine, online erschienen am 31.03.2026. Verfasst von Xiaobo Yang und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, C…. Hauptthemen laut MEDLINE: Propofol, Hypnotics and Sedatives, Benzodiazepines, Procedural Sedation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Key Clinical Research Initiative Program of Union Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To explore the efficacy and safety of remimazolam besylate in short-term sedation in the ICU in comparison with propofol. METHOD: A multicenter, randomized, single-blind, non-inferiority trial was conducted in mechanically ventilated patients, who needed light sedation, defined as Richmond Agitation-Sedation Scale (RASS) scores between -2 and + 1. The primary outcome was successful sedation, which was defined as no rescue sedative administered during the study drug infusion period while maintaining RASS scores between -2 and + 1 for at least 70% of the total infusion time. RESULTS: A total of 164 participants were included and randomized equally into the remimazolam group and the propofol group. Remimazolam was continuously infused for 10.5 [8.1-14.7] h and propofol for 11.0 [7.0-14.3] h (p = 0.534). The median average maintaining dose of remimazolam and propofol was 0.20 [0.19-0.30] mg·kg⁻1·h⁻1 and 0.61 [0.30-1.17] mg·kg⁻1·h⁻1, respectively. The percentage of participants successfully sedated in both groups was 97.5% (p = 0.497) with a difference of 0 (95% confidence interval (CI) -6.5% to 6.4%), above the predefined non-inferiority margin of -8%. There was no significant difference in the mean percentage of time with target RASS scores between the remimazolam group (88.6%; 95% CI: 84.2%-92.9%) and the propofol group (89.4%; 95% CI: 85.0%-93.8%) (p = 0.543). CONCLUSION: Remimazolam besylate could be non-inferior to propofol for achieving successful short-term light sedation in the ICU. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05782894 on Feb 18th, 2023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropofolHypnotics and SedativesBenzodiazepinesProcedural SedationHumansSingle-Blind MethodIntensive Care UnitsFemaleMaleMiddle AgedRespiration, ArtificialAged

Stichwörter der Autor:innen

Intensive care unitLight sedationPropofolRemimazolamRichmond Agitation–Sedation Scale

Substanzen

PropofolHypnotics and SedativesremimazolamBenzodiazepines

Autor:innen und Institutionen

  • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China. want.tofly@aliyun.com.
  • Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
  • Department of Critical Care Medicine, Yichang Central People's Hospital, Yichang, Hubei Province, China.
  • Department of Critical Care Medicine, The First Hospital of Changsha, Changsha, Hunan Province, China.
  • Department of Critical Care Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu Province, China.
  • Department of Critical Care Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.

Förderung

  • Key Clinical Research Initiative Program of Union Hospital

Zitieren

APA

Yang, X., Pan, J., Gong, X., Lv, A., Liang, F., Liu, J., Li, D., Fu, S., Pan, A., Yu, L., Zhang, L., Chen, T., Zhan, L., Qin, B., Lin, F., Xiong, X., Zhu, Y., He, Z., Sun, R., …, & Shang, Y. (2026). Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial. Intensive Care Medicine, 52(5), 1001-1011. https://doi.org/10.1007/s00134-026-08381-x

Vancouver

Yang X, Pan J, Gong X, Lv A, Liang F, Liu J, et al. Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial. Intensive Care Medicine. 2026;52(5):1001-1011. doi:10.1007/s00134-026-08381-x

BibTeX
@article{Yang2026,
  author = {Yang, Xiaobo and Pan, Jingye and Gong, Xun and Lv, Ailian and Liang, Fengming and Liu, Jing and Li, Dezhong and Fu, Shouzhi and Pan, Aijun and Yu, Li and Zhang, Lina and Chen, Tao and Zhan, Liying and Qin, Bingyu and Lin, Fenghui and Xiong, Xuming and Zhu, Ying and He, Zhihui and Sun, Renhua and Sun, Tongwen and Qian, Songzan and Wen, Deliang and Zou, Xiaojing and Qi, Hong and Shu, Huaqing and Song, Liping and Wang, Chunhua and Shang, You},
  title = {Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial},
  journal = {Intensive Care Medicine},
  year = {2026},
  volume = {52},
  number = {5},
  pages = {1001--1011},
  doi = {10.1007/s00134-026-08381-x}
}
Kostenlos starten →